Navidea Biopharmaceuticals, Inc. NAVB, a biopharmaceutical company
focused on precision diagnostic radiopharmaceuticals, today announced
highlights of data from its Lymphoseek^® (technetium Tc 99m tilmanocept)
Injection studies in patients with breast cancer, melanoma and head and neck
cancer that were presented at the recent Joint International Oncology Congress
(JIOC), from May 27-29, 2013. Six studies were presented, featuring new
technical insights on the unique binding mechanism of Lymphoseek and
comparative performance characteristics of the product in the clinical
setting.
“Data from a pilot study of Lymphoseek, taken together with the key benefits
of the product that were highlighted at JIOC this week, further demonstrate
how Lymphoseek is a promising precision diagnostic, delivering benefit for
patients and physicians,” said Frederick O. Cope, Ph.D., Senior Vice President
and Chief Scientific Officer at Navidea Biopharmaceuticals. “We believe that
as physicians understand how Lymphoseek was purposely designed to function at
the molecular level, that they will appreciate the utility that precision
receptor targeting brings to the clinical setting for lymphatic mapping. We
look forward to continued advances with Lymphoseek and providing additional
results from future investigator-initiated studies as they become available.”
Three presentations detailed the mechanism through which tilmanocept
selectively targets and tightly binds to receptors found in lymph nodes. Dr.
Larry Schlesinger and colleagues described the CD206-specific binding
properties of tilmanocept, noting that tilmanocept accumulation in
tumor-positive sentinel lymph nodes in head and neck cancer was even greater
than what was observed in tumor-negative sentinel nodes. Sentinel lymph nodes
that were tumor-positive recruited significant numbers of dendritic cells
compared to tumor-negative sentinel lymph nodes and non-sentinel lymph nodes,
resulting in a 10-fold increase in tilmanocept uptake in tumor-positive nodes
than in nodes that were tumor-negative.
Comparative clinical performance characteristics of tilmanocept against those
of non-receptor targeted colloidal materials used in the United States and
Europe were also highlighted at the Congress. Dr. Alice Chung and colleagues
presented data from a meta-analysis of tilmanocept results and a comprehensive
literature review of European practice in sentinel lymph node mapping. The
data demonstrated a statistical performance difference between tilmanocept and
European colloidal materials in breast cancer patients. An initial pilot study
conducted by Dr. Nathan Hall and colleagues examined the uptake and injection
site clearance time of tilmanocept and 99m technetium sulfur colloid in breast
cancer patients using dynamic SPECT/CT.
The Co-chairs of The Joint International Oncology Congress made a joint
comment relating to presentations made at the Congress: “The international
faculty and experts attending this year's JIOC found the sessions on recent
advances in targeted agents for lymphatic mapping and sentinel lymph node
biopsy both educational and stimulating for scientific discussion. Attendees
were interested to learn more about how tilmanocept functions at the molecular
level and to be updated on its clinical performance. Part of our mission for
JIOC is to help expand understanding and practices of clinical oncologists and
to bring the clinical relevance of cancer metastasis to basic scientists, and
sessions such as these help us meet that goal,” said Armando E. Giuliano, MD,
FDACS, FRCSEd, President, International Sentinel Node Society and Executive
Vice Chair of Surgery, Surgical Oncology, Department of Surgery and Associate
Director, Surgical Oncology, Samuel Oschin Comprehensive Cancer Institute at
Cedars-Sinai Medical Center in Los Angeles, CA; and Stanley P. L. Leong, MD,
FACS, President, Sentinel Node Oncology Foundation and Head of Melanoma
Surgery and Chief of Cutaneous Surgery at the California Pacific Medical
Center and Research Institute in San Francisco.
Full content of all JIOC abstracts may be found at:
http://www.sn-cancermets.org/docs/caa.pdf.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: News
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in